Assessing the allergenicity of proteins introduced into genetically modified crops using specific human IgE assays

Richard E. Goodman, John N. Leach

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Global commercial production of genetically modified (GM) crops has grown to over 67 million hectares annually, primarily of herbicide-tolerant and insect protection crop varieties. GM crops are produced by the insertion of specific genes that either encode a protein, or a regulatory RNA sequence. A comprehensive safety evaluation is conducted for each new commercial GM crop, including an assessment of the potential allergenicity of any newly introduced protein. If the gene was derived from an allergenic organism, or the protein sequence is highly similar to a known allergen, immunoassays, e.g., Western blot assays and enzyme-linked immunosorbent assay tests, are performed to identify protein-specific IgE binding by sera of individuals allergic to the gene source, or the source of the sequence-matched allergen. Although such assays are commonly used to identify previously unknown allergens, criteria have not been established to demonstrate that a protein is unlikely to cause allergic reactions. This review discusses factors that affect the predictive value of these tests, including clinical selection criteria for serum donors, selection of blocking reagents to reduce nonspecific antibody binding, inhibition assays to verify specificity of binding, and scientifically justified limits of detection (sensitivity) in the absence of information regarding biological thresholds.

Original languageEnglish (US)
Pages (from-to)1423-1432
Number of pages10
JournalJournal of AOAC International
Volume87
Issue number6
StatePublished - Nov 1 2004

Fingerprint

allergenicity
Immunoglobulin E
Crops
Assays
allergens
assay
Allergens
crop
protein
assays
crops
Ribonucleic Acid Regulatory Sequences
Genes
Proteins
proteins
gene
Predictive Value of Tests
serum
Galectin 3
Donor Selection

ASJC Scopus subject areas

  • Analytical Chemistry
  • Food Science
  • Environmental Chemistry
  • Agronomy and Crop Science
  • Pharmacology

Cite this

Assessing the allergenicity of proteins introduced into genetically modified crops using specific human IgE assays. / Goodman, Richard E.; Leach, John N.

In: Journal of AOAC International, Vol. 87, No. 6, 01.11.2004, p. 1423-1432.

Research output: Contribution to journalArticle

@article{dcf4804c5ce94c199a85fa68ac72b2b2,
title = "Assessing the allergenicity of proteins introduced into genetically modified crops using specific human IgE assays",
abstract = "Global commercial production of genetically modified (GM) crops has grown to over 67 million hectares annually, primarily of herbicide-tolerant and insect protection crop varieties. GM crops are produced by the insertion of specific genes that either encode a protein, or a regulatory RNA sequence. A comprehensive safety evaluation is conducted for each new commercial GM crop, including an assessment of the potential allergenicity of any newly introduced protein. If the gene was derived from an allergenic organism, or the protein sequence is highly similar to a known allergen, immunoassays, e.g., Western blot assays and enzyme-linked immunosorbent assay tests, are performed to identify protein-specific IgE binding by sera of individuals allergic to the gene source, or the source of the sequence-matched allergen. Although such assays are commonly used to identify previously unknown allergens, criteria have not been established to demonstrate that a protein is unlikely to cause allergic reactions. This review discusses factors that affect the predictive value of these tests, including clinical selection criteria for serum donors, selection of blocking reagents to reduce nonspecific antibody binding, inhibition assays to verify specificity of binding, and scientifically justified limits of detection (sensitivity) in the absence of information regarding biological thresholds.",
author = "Goodman, {Richard E.} and Leach, {John N.}",
year = "2004",
month = "11",
day = "1",
language = "English (US)",
volume = "87",
pages = "1423--1432",
journal = "Journal of AOAC International",
issn = "1060-3271",
publisher = "AOAC International",
number = "6",

}

TY - JOUR

T1 - Assessing the allergenicity of proteins introduced into genetically modified crops using specific human IgE assays

AU - Goodman, Richard E.

AU - Leach, John N.

PY - 2004/11/1

Y1 - 2004/11/1

N2 - Global commercial production of genetically modified (GM) crops has grown to over 67 million hectares annually, primarily of herbicide-tolerant and insect protection crop varieties. GM crops are produced by the insertion of specific genes that either encode a protein, or a regulatory RNA sequence. A comprehensive safety evaluation is conducted for each new commercial GM crop, including an assessment of the potential allergenicity of any newly introduced protein. If the gene was derived from an allergenic organism, or the protein sequence is highly similar to a known allergen, immunoassays, e.g., Western blot assays and enzyme-linked immunosorbent assay tests, are performed to identify protein-specific IgE binding by sera of individuals allergic to the gene source, or the source of the sequence-matched allergen. Although such assays are commonly used to identify previously unknown allergens, criteria have not been established to demonstrate that a protein is unlikely to cause allergic reactions. This review discusses factors that affect the predictive value of these tests, including clinical selection criteria for serum donors, selection of blocking reagents to reduce nonspecific antibody binding, inhibition assays to verify specificity of binding, and scientifically justified limits of detection (sensitivity) in the absence of information regarding biological thresholds.

AB - Global commercial production of genetically modified (GM) crops has grown to over 67 million hectares annually, primarily of herbicide-tolerant and insect protection crop varieties. GM crops are produced by the insertion of specific genes that either encode a protein, or a regulatory RNA sequence. A comprehensive safety evaluation is conducted for each new commercial GM crop, including an assessment of the potential allergenicity of any newly introduced protein. If the gene was derived from an allergenic organism, or the protein sequence is highly similar to a known allergen, immunoassays, e.g., Western blot assays and enzyme-linked immunosorbent assay tests, are performed to identify protein-specific IgE binding by sera of individuals allergic to the gene source, or the source of the sequence-matched allergen. Although such assays are commonly used to identify previously unknown allergens, criteria have not been established to demonstrate that a protein is unlikely to cause allergic reactions. This review discusses factors that affect the predictive value of these tests, including clinical selection criteria for serum donors, selection of blocking reagents to reduce nonspecific antibody binding, inhibition assays to verify specificity of binding, and scientifically justified limits of detection (sensitivity) in the absence of information regarding biological thresholds.

UR - http://www.scopus.com/inward/record.url?scp=10844232415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10844232415&partnerID=8YFLogxK

M3 - Article

C2 - 15675455

AN - SCOPUS:10844232415

VL - 87

SP - 1423

EP - 1432

JO - Journal of AOAC International

JF - Journal of AOAC International

SN - 1060-3271

IS - 6

ER -